论文部分内容阅读
现已广泛应用IFN-α来治疗丙型肝炎,其最佳的用法是300万单位(U),每周3次,至少1年,但其效果尚不令人满意。NSAID在体外能增强IFN-α的抗病毒作用。小型试验见IFN-α联合各型的NSAID对慢性丙肝有生化上的效果。此研究目的为比较IFN-α 2b联合2种不同剂量苯酮苯丙酸(ketoprofen,kp)与单用IFN-α2b 6个月对未曾治疗过的慢性HCV相关肝病的效果和安全性。 病人与方法:70例代偿期HCV相关慢性肝病者符合下列条件:(a)6个月内至少2次血清ALT在正常上限2倍以上;(b)抗HCV阳
Now that IFN-α is widely used to treat hepatitis C, its best use is 300 million units (U) three times a week for at least one year, but its effect is not yet satisfactory. NSAID can enhance the antiviral effect of IFN-α in vitro. Small trials have shown that IFN-α combined with each type of NSAID has a biochemical effect on chronic hepatitis C. The aim of this study was to compare the efficacy and safety of IFN-α 2b with two different doses of ketoprofen (kp) and IFN-α2b alone for six months on untreated chronic HCV-related liver disease. PATIENTS AND METHODS: Seventy patients with decompensated HCV-associated chronic liver disease met the following criteria: (a) serum ALT was more than twice the upper limit of normal within 6 months; (b) anti-HCV